Vaccines: latest news

Vaccines resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

Vaccines features

Vaccines news from aidsmap

More news

Vaccines news selected from other sources

  • Big improvements in HIV vaccine production

    Technical advances in vaccine production should shorten the time to clinical trials, breaking the logjam of promising new candidate vaccines waiting to be tested.

    06 February 2018 | Science Daily
  • Setting the Standard: New prevention trials in the era of oral PrEP

    There’s a lot going on in the world of HIV prevention research right now. One key issue is how participants might access oral PrEP as part of HIV prevention trials. It may seem simple: trial participants have the right to the highest standard of HIV prevention and care as part of participation. But the ethics, trial design issues and the mechanisms by which interventions are provided as standard of care are quite complex. Opinions differ and politics abound.

    08 December 2017 | AVAC
  • Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

    The new, large-scale study (HVTN 705/HPX2008), also known as “Imbokodo”, will evaluate whether the investigational Janssen vaccine regimen is safe and able to reduce the incidence of HIV infection among 2,600 women in sub-Saharan Africa.

    30 November 2017 | Johnson & Johnson press release
  • Four big insights into HIV/AIDS that provide hope of finding a vaccine

    African researchers have been performing cutting-edge research to contribute to addressing the HIV epidemic. The sub-Saharan African Network for TB/HIV Research Excellence has been at the forefront of this research and has provided some important insights into how the virus spreads as well as the immune mechanisms that enable some people to control the virus without antiretroviral drugs.

    24 November 2017 | The Conversation
  • Durable end to the HIV/AIDS pandemic likely will require an HIV vaccine

    Theoretically, effective global implementation of existing HIV treatment and prevention tools could end the HIV/AIDS pandemic. However, from a practical standpoint, ending the HIV/AIDS pandemic without a vaccine is unlikely, according to a new commentary from Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

    10 October 2017 | Eurekalert Medicine & Health
  • Why HPV Vaccination Rates Remain Low in Rural States

    The problem the vaccine has faced is its link to a taboo in American culture: sexual activity among teenagers. Health-care providers are the biggest hurdle to getting more children vaccinated.

    11 September 2017 | MIT Technology Review
  • The 2017 Pipeline Report

    Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

    19 July 2017 | Treatment Action Group
  • Immune system may keep body from neutralizing HIV-1 virus

    Researchers at the University of Colorado Anschutz Medical Campus have discovered that a process protecting the body from autoimmune disease appears to prevent it from creating antibodies that can neutralize the HIV-1 virus, a finding that could possibly help lead to a vaccine that stimulates production of these antibodies.

    11 July 2017 | Eurekalert Medicine & Health
  • First vaccine shows gonorrhoea protection

    A vaccine has for the first time been shown to protect against gonorrhoea, scientists in New Zealand say. The vaccine, originally developed to stop an outbreak of meningitis B, was given to about a million adolescents in New Zealand between 2004 and 2006. Researchers at the University of Auckland analysed data from sexual health clinics and found gonorrhoea cases had fallen 31% in those vaccinated. The meachanism of protection is unknown. This particular vaccine is no longer available but the UK has been using a similar vaccine, though whether it will protect is also unknown.

    11 July 2017 | BBC
  • Does it ever make sense to target HPV screening at HIV-infected individuals?

    A number of recent studies have considered the case for HPV-related cancer prevention interventions that are targeted at specific populations. A recent study suggests that, given their more rapid progression to precancerous conditions, HIV positive women in sub-Saharan Africa should be given the multivalent HPV vaccine, as it already is to HIV-positive MSM in some high-income settings.

    05 July 2017 | BMJ
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.